ProQR Therapeutics NV is a clinical stage biopharmaceutical company, which engages in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases with a focus on inherited retinal diseases. The company is headquartered in Leiden, Zuid-Holland and currently employs 166 full-time employees. The company went IPO on 2014-09-18. The firm is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Main purpose of the Company is advancement of its Axiomer RNA-editing platform technology. That technology uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unaddressed needs. The firm operates research pipeline that contains of RNA Therapy and AX-0810 Cholestatic Diseases (NTCP).
Follow-Up Questions
Who is the CEO of ProQR Therapeutics NV?
Mr. Daniel de Boer is the Chief Executive Officer of ProQR Therapeutics NV, joining the firm since 2012.
What is the price performance of PRQR stock?
The current price of PRQR is $2.93, it has increased 5.39% in the last trading day.
What are the primary business themes or industries for ProQR Therapeutics NV?
ProQR Therapeutics NV belongs to Biotechnology industry and the sector is Health Care
What is ProQR Therapeutics NV market cap?
ProQR Therapeutics NV's current market cap is $308.6M
Is ProQR Therapeutics NV a buy, sell, or hold?
According to wall street analysts, 11 analysts have made analyst ratings for ProQR Therapeutics NV, including 5 strong buy, 9 buy, 1 hold, 0 sell, and 5 strong sell
